Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joth Jacobson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Statistical Methods in Medical Research|July 4, 2002
Partitioning and peeling for constructing prognostic groupsMichael LeBlanc, Joth Jacobson, John Crowley
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 13, 2009
Fracture of the GORE HELEX septal occluder: associated factors and clinical outcomesThomas Fagan, Dennis Dreher, Warren Cutright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trialsBrian G M Durie, Joth Jacobson, Bart Barlogie, et al.
American Heart Journal|April 29, 2006
Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluderLarry A Latson, Thomas K Jones, Joth Jacobson, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|November 2, 2017
Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical StudyScott E Kasner, Lars Thomassen, Lars Søndergaard, et al.
Investigational New Drugs|November 27, 2002
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group studyCary A Presant, Joth Jacobson, Walter Wolf, et al.
Blood|September 13, 2003
Treatment of multiple myelomaBart Barlogie, John Shaughnessy, Guido Tricot, et al.
Blood|March 1, 2003
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survivalKai-Da Wu, Lisa M Orme, John Shaughnessy, et al.
Journal of the American College of Cardiology|June 5, 2007
Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defectsThomas K Jones, Larry A Latson, Evan Zahn, et al.
British Journal of Haematology|July 25, 2003
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson, Bart Barlogie, John Shaughnessy, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Statistical Methods in Medical Research|July 4, 2002
Partitioning and peeling for constructing prognostic groupsMichael LeBlanc, Joth Jacobson, John Crowley
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 13, 2009
Fracture of the GORE HELEX septal occluder: associated factors and clinical outcomesThomas Fagan, Dennis Dreher, Warren Cutright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trialsBrian G M Durie, Joth Jacobson, Bart Barlogie, et al.
American Heart Journal|April 29, 2006
Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluderLarry A Latson, Thomas K Jones, Joth Jacobson, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|November 2, 2017
Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical StudyScott E Kasner, Lars Thomassen, Lars Søndergaard, et al.
Investigational New Drugs|November 27, 2002
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group studyCary A Presant, Joth Jacobson, Walter Wolf, et al.
Blood|September 13, 2003
Treatment of multiple myelomaBart Barlogie, John Shaughnessy, Guido Tricot, et al.
Blood|March 1, 2003
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survivalKai-Da Wu, Lisa M Orme, John Shaughnessy, et al.
Journal of the American College of Cardiology|June 5, 2007
Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defectsThomas K Jones, Larry A Latson, Evan Zahn, et al.
British Journal of Haematology|July 25, 2003
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplantsJoth Jacobson, Bart Barlogie, John Shaughnessy, et al.
Pageof 2